Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), José Baselga(Harvard University), Sriram Sathyanarayanan(Boston Biomedical Research Institute), Johanna C. Bendell(Dana-Farber Cancer Institute), Youyuan Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sharda Jha(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher Winter(Dana-Farber Cancer Institute), Jason P. Frazier(Rosetta Stone (United States)), Desamparados Roda(Institute of Cancer Research), Mark N. Stein(Cornell University), Richard A. Klinghoffer(Tempus Labs (United States)), Irene Braña(Vall d'Hebron Institute of Oncology), Ann Leighton-Swayze, Andrés Cervantes(INCLIVA Health Research Institute), Yang Song(Merck & Co., Inc., Rahway, NJ, USA (United States)), Theresa Zhang(Human Genome Sciences (United States)), Brian B. Haines(Boston Biomedical Research Institute), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 56
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k